Developer docs
API playgroundTry for free, no card

Search company profiles

Indivi

Full company profile

uuid0000iz8

Namestring
Indivi
Legal namestring
Indivi AG
Websiteurl
indivi.io
Company typeenum
Private
Founded yearint
2014
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital biomarkers, neurology clinical trials, smartphone health assessments, multiple sclerosis monitoring, Parkinson's disease endpoints
Industry2 codes
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Digital Biomarker Platform for Neuroscience Clinical Trials
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Digital biomarker platform licensing and services
TypeSubscription Recurring
Description

Provides digital measurement technology and services to pharmaceutical companies and academic teams conducting neuroscience clinical trials. Revenue derived from licensing technology, providing deployment services, and data processing for clinical trials.

eurozone.einnews.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 2 records shown
1dreaMS MD
Description

CE Mark (Class I) smartphone technology for patients with multiple sclerosis. A Software Medical Device cleared by the European Medicine Agency (EMA) that assesses patients' neurological function during daily activities, focusing on movement, dexterity, cognition, and vision.

indivi.io
+1 more record
Core offering1 text field

Indivi develops and licenses a smartphone-based digital biomarker platform that transforms any smartphone into a digital measurement laboratory for neurological function assessment in clinical trials. The platform combines dreaMS MD (CE Mark Class I Software Medical Device for MS) and Konectom (licensed from Biogen for Parkinson's disease) to measure motor, cognitive, vision, balance, dexterity, and voice functions, providing end-to-end digital endpoint services from protocol design through regulatory and scientific reporting for pharmaceutical, biotech, and academic research sponsors.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Reduced sample size and/or increased probability of success in proof-of-concept trials through higher SNR digital endpoints
+1 more record
Product overview1 text field

Indivi is a TechBio company offering a unified digital biomarker platform for neuroscience research and development. The core offering combines two major smartphone-based technologies: Konectomᵀᴹ (licensed from Biogen) for digital biomarker assessment in Parkinson's disease, and dreaMSᴹᴰ (Indivi's CE-marked medical device) for multiple sclerosis monitoring. The platform measures movement, cognition, vision, balance, dexterity, and voice functions. The technology stack consists of Indivi App (smartphone data capture), Indivi Cloud (real-time secured data transfer with automated quality checks), and Indivi PRO (clinical trial management platform for pharma companies and academia). Through end-to-end digital endpoint development services, the company supports clinical trials from protocol design through regulatory and scientific reporting.

Product and service5 records
1dreaMS MD
CategoryDigital Biomarker Software Medical Device
Description

CE Mark (Class I) cleared smartphone-based Software Medical Device for monitoring neurological functions in multiple sclerosis patients, assessing movement, dexterity, cognition, and vision during daily activities. Algorithmically analyzed digital metrics feed clinical trials and patient monitoring. For pharmaceutical sponsors and clinical research organizations.

2Konectom
CategoryDigital Biomarker Platform
Description

Smartphone-based digital biomarker platform licensed from Biogen for remote assessment of neurological functions in Parkinson's disease clinical trials. Provides precise, frequent measurement of disease evolution including movement, dexterity, cognition, and vision. For pharmaceutical sponsors.

3Indivi PRO
CategoryClinical Trial Management Platform
Description

Advanced clinical trial management platform for the pharmaceutical industry, clinical research organizations, and academia. Provides end-to-end services throughout clinical trials from protocol design to regulatory and scientific reporting, including adaptive interim analyses, responsive digital measure identification, and statistical analysis.

4Indivi App
CategoryData Capture Application
Description

Unified smartphone data capture system that combines assessments from multiple partner devices and apps, transforming any smartphone into a digital measurement laboratory for precision medicine development.

5Indivi Cloud
CategoryCloud Infrastructure
Description

Secure cloud infrastructure enabling real-time data transfer from the Indivi App with automated data integrity and quality checks, and regulatory-compliant data processing and analysis.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Multi-year strategic collaboration where Biogen licensed Konectomᵀᴹ to Indivi. Indivi took over digital management of the Phase 2b LUMA study evaluating BIIB122 in early-stage Parkinson's disease. Companies aim to develop and validate novel digital endpoints in Parkinson's disease and explore additional disease areas.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

Strategic partnership announced October 2025 combining neuro-electrophysiology with digital health technologies to create unified R&D framework for early-phase treatments in Alzheimer's and Parkinson's disease. Aim to improve drug development success rates by enabling earlier and more definitive signals in clinical trials.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Partnership announced May 2026 to integrate Indivi's digital biomarker platform into Herantis' Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Close research cooperation with RC2NB, an internationally renowned institution embedded in Basel University Hospital and University of Basel. RC2NB specializes in development and integration of innovative tools that comprehensively characterize disease processes in MS and other neuroimmune/neurodegenerative diseases. Co-CEOs are Profs. Cristina Granziera and Ludwig Kappos.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Koneksa Health develops digital biomarker platforms and remote patient monitoring tools for clinical trials across multiple therapeutic areas including CNS and respiratory. It is the most directly comparable peer to Indivi, serving pharma sponsors with smartphone/wearable-based endpoints and validated digital measures.

TypeDirect peer
Description

VivoSense provides wearable sensor and digital endpoint analytics for clinical trials, with deep focus on neuroscience and rare disease. It competes with Indivi in the smartphone/wearable-derived digital biomarker space serving pharmaceutical sponsors.

TypeDirect peer
Description

Cambridge Cognition develops digital cognitive assessments and cloud-based CNS measurement tools sold to pharmaceutical companies and academic researchers. It directly overlaps with Indivi's cognitive assessment and ADAPT-MCI-style cognitive endpoint offerings.

TypeDirect peer
Description

ActiGraph manufactures wearable activity monitors and clinical trial digital endpoint solutions used in pharma studies. Indivi and ActiGraph are already technology/integration partners and serve overlapping CNS clinical trial sponsors.

TypeBroad incumbent
Description

Clario is a large clinical trial technology and eCOA/ePRO vendor serving pharma and biotech across therapeutic areas. It competes with Indivi at the digital endpoint layer but as part of a much broader portfolio of trial technology services.

TypeBroad incumbent
Description

Medidata offers EDC, eCOA, and a broad clinical trial technology platform used by major pharma sponsors. It is a broad incumbent that competes with Indivi's Indivi PRO platform for clinical trial endpoint and data management engagements.

TypeEmerging player
Description

Evidation Health generates patient-generated health data and digital biomarkers from smartphones and wearables for research and pharma collaborations. It is an emerging competitor in the digital biomarker measurement space with broader chronic disease focus.

TypeEmerging player
Description

AiCure provides AI-driven digital biomarkers and patient engagement tools for clinical trials, with CNS experience. It overlaps with Indivi at the digital endpoint and trial-monitoring layer, particularly in CNS indications.

TypeBroad incumbent
Description

Roche is a major pharma sponsor and has internal digital biomarker and CNS endpoint capabilities. Several Indivi executives are ex-Roche (e.g., CMO, Head of Biostatistics), and Roche represents both a potential customer and a broad incumbent competitor building similar capabilities.

TypeOthers
Description

Biogen is both a core customer and licensor (Konectom) to Indivi. While not a direct competitor, Biogen's broader digital health ambitions make it a strategic partner/incumbent with overlapping technology interests in CNS digital endpoints.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds10 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Indivi

Digital Biomarker Platform for Neuroscience Clinical Trialsindivi.io

Indivi firmographics

Firmographics
Name
Indivi
Legal name
Indivi AG
Website
https://indivi.io
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

Indivi industry classification

Industry
Product category
Digital Biomarker Platform for Neuroscience Clinical Trials
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLACAOAB
eCOA/ePRO/eDiary & Patient-Facing Data Collection
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Trials & Research Informatics (eCOA/ePRO/EDC)
SECONDARYHLACAFAO
Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms

Keywords

  • Digital biomarkers
  • Neurology clinical trials
  • Smartphone health assessments
  • Multiple sclerosis monitoring
  • Parkinson's disease endpoints

Where Indivi is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Indivi business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. Digital biomarker platform licensing and services: Provides digital measurement technology and services to pharmaceutical companies and academic teams conducting neuroscience clinical trials. Revenue derived from licensing technology, providing deployment services, and data processing for clinical trials.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Indivi product offering

Product offering

Core offering

Indivi develops and licenses a smartphone-based digital biomarker platform that transforms any smartphone into a digital measurement laboratory for neurological function assessment in clinical trials. The platform combines dreaMS MD (CE Mark Class I Software Medical Device for MS) and Konectom (licensed from Biogen for Parkinson's disease) to measure motor, cognitive, vision, balance, dexterity, and voice functions, providing end-to-end digital endpoint services from protocol design through regulatory and scientific reporting for pharmaceutical, biotech, and academic research sponsors.

Product overview

Indivi is a TechBio company offering a unified digital biomarker platform for neuroscience research and development. The core offering combines two major smartphone-based technologies: Konectomᵀᴹ (licensed from Biogen) for digital biomarker assessment in Parkinson's disease, and dreaMSᴹᴰ (Indivi's CE-marked medical device) for multiple sclerosis monitoring. The platform measures movement, cognition, vision, balance, dexterity, and voice functions. The technology stack consists of Indivi App (smartphone data capture), Indivi Cloud (real-time secured data transfer with automated quality checks), and Indivi PRO (clinical trial management platform for pharma companies and academia). Through end-to-end digital endpoint development services, the company supports clinical trials from protocol design through regulatory and scientific reporting.

Differentiator

Problem solved

Functional benefit

Brands

  • dreaMS MD: CE Mark (Class I) smartphone technology for patients with multiple sclerosis. A Software Medical Device cleared by the European Medicine Agency (EMA) that assesses patients' neurological function during daily activities, focusing on movement, dexterity, cognition, and vision.
  • Konectom

Products and services

  • dreaMS MD CE Mark (Class I) cleared smartphone-based Software Medical Device for monitoring neurological functions in multiple sclerosis patients, assessing movement, dexterity, cognition, and vision during daily activities. Algorithmically analyzed digital metrics feed clinical trials and patient monitoring. For pharmaceutical sponsors and clinical research organizations.
  • Konectom Smartphone-based digital biomarker platform licensed from Biogen for remote assessment of neurological functions in Parkinson's disease clinical trials. Provides precise, frequent measurement of disease evolution including movement, dexterity, cognition, and vision. For pharmaceutical sponsors.
  • Indivi PRO Advanced clinical trial management platform for the pharmaceutical industry, clinical research organizations, and academia. Provides end-to-end services throughout clinical trials from protocol design to regulatory and scientific reporting, including adaptive interim analyses, responsive digital measure identification, and statistical analysis.
  • Indivi App Unified smartphone data capture system that combines assessments from multiple partner devices and apps, transforming any smartphone into a digital measurement laboratory for precision medicine development.
  • Indivi Cloud Secure cloud infrastructure enabling real-time data transfer from the Indivi App with automated data integrity and quality checks, and regulatory-compliant data processing and analysis.

Quantifiable outcome

  • Reduced sample size and/or increased probability of success in proof-of-concept trials through higher SNR digital endpoints
  • +1 more outcomes

Companies that use Indivi

Customer profile

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Indivi technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Indivi partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core and flagship.

  • BiogencoreStrategic or Co-development PartnerMulti-year strategic collaboration where Biogen licensed Konectomᵀᴹ to Indivi. Indivi took over digital management of the Phase 2b LUMA study evaluating BIIB122 in early-stage Parkinson's disease. Companies aim to develop and validate novel digital endpoints in Parkinson's disease and explore additional disease areas.
  • Clouds of CareflagshipStrategic or Co-development PartnerStrategic partnership announced October 2025 combining neuro-electrophysiology with digital health technologies to create unified R&D framework for early-phase treatments in Alzheimer's and Parkinson's disease. Aim to improve drug development success rates by enabling earlier and more definitive signals in clinical trials.
  • Herantis PharmacoreStrategic or Co-development PartnerPartnership announced May 2026 to integrate Indivi's digital biomarker platform into Herantis' Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes.
  • RC2NB (Research Center for Clinical Neuroimmunology and Neuroscience Basel)coreStrategic or Co-development PartnerClose research cooperation with RC2NB, an internationally renowned institution embedded in Basel University Hospital and University of Basel. RC2NB specializes in development and integration of innovative tools that comprehensively characterize disease processes in MS and other neuroimmune/neurodegenerative diseases. Co-CEOs are Profs. Cristina Granziera and Ludwig Kappos.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Indivi competitors and assessment

Company assessment

Direct peers

  • Koneksa Health: Koneksa Health develops digital biomarker platforms and remote patient monitoring tools for clinical trials across multiple therapeutic areas including CNS and respiratory. It is the most directly comparable peer to Indivi, serving pharma sponsors with smartphone/wearable-based endpoints and validated digital measures.
  • VivoSense: VivoSense provides wearable sensor and digital endpoint analytics for clinical trials, with deep focus on neuroscience and rare disease. It competes with Indivi in the smartphone/wearable-derived digital biomarker space serving pharmaceutical sponsors.
  • Cambridge Cognition: Cambridge Cognition develops digital cognitive assessments and cloud-based CNS measurement tools sold to pharmaceutical companies and academic researchers. It directly overlaps with Indivi's cognitive assessment and ADAPT-MCI-style cognitive endpoint offerings.
  • ActiGraph: ActiGraph manufactures wearable activity monitors and clinical trial digital endpoint solutions used in pharma studies. Indivi and ActiGraph are already technology/integration partners and serve overlapping CNS clinical trial sponsors.

Broad incumbents

  • Clario (formerly ERT/Bioclinica): Clario is a large clinical trial technology and eCOA/ePRO vendor serving pharma and biotech across therapeutic areas. It competes with Indivi at the digital endpoint layer but as part of a much broader portfolio of trial technology services.
  • Medidata (Dassault Systèmes): Medidata offers EDC, eCOA, and a broad clinical trial technology platform used by major pharma sponsors. It is a broad incumbent that competes with Indivi's Indivi PRO platform for clinical trial endpoint and data management engagements.
  • Roche (Digital Health / Roche Pharma): Roche is a major pharma sponsor and has internal digital biomarker and CNS endpoint capabilities. Several Indivi executives are ex-Roche (e.g., CMO, Head of Biostatistics), and Roche represents both a potential customer and a broad incumbent competitor building similar capabilities.

Emerging players

  • Evidation Health: Evidation Health generates patient-generated health data and digital biomarkers from smartphones and wearables for research and pharma collaborations. It is an emerging competitor in the digital biomarker measurement space with broader chronic disease focus.
  • AiCure: AiCure provides AI-driven digital biomarkers and patient engagement tools for clinical trials, with CNS experience. It overlaps with Indivi at the digital endpoint and trial-monitoring layer, particularly in CNS indications.

Others

  • Biogen: Biogen is both a core customer and licensor (Konectom) to Indivi. While not a direct competitor, Biogen's broader digital health ambitions make it a strategic partner/incumbent with overlapping technology interests in CNS digital endpoints.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Indivi social profiles

Digital presence

Indivi compliance and trust

Trust signal

Compliance4 records

Indivi financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Indivi leadership team

Management profile

Number of profiles

Profiles11 records

Indivi funding detail

Funding detail

Funding overview

Funding rounds10 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Indivi M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Indivi

What does Indivi do?

Indivi develops and licenses a smartphone-based digital biomarker platform that transforms any smartphone into a digital measurement laboratory for neurological function assessment in clinical trials. The platform combines dreaMS MD (CE Mark Class I Software Medical Device for MS) and Konectom (licensed from Biogen for Parkinson's disease) to measure motor, cognitive, vision, balance, dexterity, and voice functions, providing end-to-end digital endpoint services from protocol design through regulatory and scientific reporting for pharmaceutical, biotech, and academic research sponsors.

Is Indivi a public or private company?

Indivi is a private company. It is classified as venture growth investor backed and is currently operating.

When was Indivi founded?

Indivi was founded in 2014. It employs 51 to 100 people.

Where is Indivi based?

Indivi is headquartered in Basel, Switzerland, in the Europe region.

How does Indivi make money?

One revenue line is on record: digital biomarker platform licensing and services.

Who are Indivi's main competitors?

Direct peers on record are Koneksa Health, VivoSense, Cambridge Cognition and ActiGraph. Broad incumbents are Clario (formerly ERT/Bioclinica), Medidata (Dassault Systèmes) and Roche (Digital Health / Roche Pharma). Emerging players are Evidation Health and AiCure. Biogen is listed as an others.

Does Indivi have an API?

No public API is recorded for Indivi.

What industry is Indivi in?

Indivi's product category is Digital Biomarker Platform for Neuroscience Clinical Trials. Its primary akta.pro industry code is HLACAOAB, eCOA/ePRO/eDiary & Patient-Facing Data Collection, with a secondary code of HLACAFAO, Data Aggregation, Interoperability & APIs for RPM (FHIR/IoMT Gateways). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mirage NewsSwiss Neurotech Indivi Acquires Imperial Spinout CogitatIndivi acquired Cogitat, an Imperial College spinout, for its AI foundation model that translates EEG data into brain-state read-outs. The deal, for an undisclosed sum, aims to help pharmaceutical companies detect early treatment effects for neurodegenerative diseases like Alzheimer's. Cogitat will operate as a business unit at Indivi.startupticker.chIndivi strengthens AI capabilities for brain analysis with Cogitat acquisitionIndivi acquired Cogitat, a UK-based company developing EEG-based deep learning models. Cogitat's NeuroRVQ foundation model won first place in the BEETL competition at NeurIPS. Indivi will use the model to detect treatment effects in brain conditions like Alzheimer's.Startup ResearcherIndivi Acquires Cogitat to Advance AI-Powered Brain MonitoringIndivi acquired Cogitat, an Imperial College London spin-out, to integrate its NeuroRVQ deep learning model for decoding cognitive function from EEG signals. The model aims to detect treatment response in Alzheimer's disease before clinical symptoms appear. NeuroRVQ will be presented at NeurIPS 2026.Dealroom.coSwiss neurotech Indivi buys Imperial spin-out Cogitat for brain monitoring | Dealroom NewsSwiss neurotech Indivi acquired Cogitat, an Imperial College London spin-out, for an undisclosed deal value. The acquisition integrates Cogitat's EEG foundation model NeuroRVQ into Indivi's platform, aiming to detect early signs of treatment response in Alzheimer's and related dementias. The deal follows recent investor backing, including a US$13.8M raise in November 2025.startupticker.chIndivi attracts Infosys Innovation Fund as strategic investorInfosys Innovation Fund has invested in Indivi, a Basel-based TechBio company specializing in digital biomarkers for neurology. This strategic partnership aims to scale Indivi's platform for detecting early treatment effects in clinical trials, leveraging Infosys' AI and technical capabilities. The collaboration seeks to improve the efficiency and accuracy of drug development for conditions like Parkinson’s disease.The Manila TimesHerantis Pharma partners with Indivi to enable detection of early treatment effects in upcoming HER-096 Phase 2 trial in Parkinson’s diseaseHerantis Pharma has partnered with Indivi to integrate Indivi's digital biomarker platform into Herantis' upcoming Phase 2 proof-of-concept trial of HER-096 for Parkinson's disease. Indivi's platform uses smartphone-based assessments of motor and cognitive function to enable more sensitive detection of treatment-related changes compared to conventional clinical assessments. Preparations for the Phase 2 study are on track, with Herantis expecting to provide additional updates following completion of study design.openPR.comTop Players and Competitive Overview in the Digital Biomarkers MarketThe digital biomarkers market is projected to reach $15.77 billion by 2030, growing at a compound annual growth rate of 26.0%, driven by investments in digital health platforms, personalized healthcare monitoring, and regulatory support. In March 2024, Switzerland-based MedTech firm Indivi partnered with Biogen to develop digital health technology for Parkinson's disease, focusing on digital endpoints and remote neurological function assessments. Additionally, Siemens Healthineers introduced the Atellica HEMA 570 and Atellica HEMA 580 hematology analyzers in May 2023 to automate blood sample analysis for high-volume testing.EIN PresswireLeclercq American Capital LLC invests in Indivi.io, a Swiss specialist in digital biomarkers for neurologyUS-based investment firm Leclercq American Capital LLC announced an equity investment in Indivi.io, a Basel (Switzerland)-based medtech company specializing in digital biomarkers for neurological diseases including multiple sclerosis, Parkinson's, and Alzheimer's. The investment amount and terms were not disclosed, but the deal aligns with Leclercq American Capital's "data biotechnology" strategy focused on companies generating clinical data, advancing analytics, and addressing high unmet medical needs. Indivi.io operates as a data-native platform serving pharmaceutical companies and academic teams in neuroscience research.startupticker.chExecutive hires to help startups scaleSix startups have made strategic executive hires to fuel their growth, with SOPHiA Genetics announcing Ross Muken as incoming CEO effective July 2026, succeeding co-founder Jurgi Camblong, while Livingdocs, Hemotune, Indivi, GlycoEra, and bNovate Technologies each appointed new C-suite leaders including COOs, CBOs, and CMOs. The article details each executive's professional background and the strategic growth objectives for their respective companies, spanning health-tech, biotech, water management, and content management sectors. These appointments reflect broader trends in startup scaling, with companies recruiting experienced leaders to accelerate business development and commercial execution.